NASDAQ:ENVB Enveric Biosciences (ENVB) Stock Price, News & Analysis $0.55 +0.01 (+1.85%) (As of 10/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Enveric Biosciences Stock (NASDAQ:ENVB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Enveric Biosciences alerts:Sign Up Key Stats Today's Range$0.49▼$0.5650-Day Range$0.41▼$0.5852-Week Range$0.36▼$2.92Volume268,917 shsAverage Volume1.95 million shsMarket Capitalization$4.38 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingBuy Company OverviewEnveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Enveric Biosciences Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks64th Percentile Overall ScoreENVB MarketRank™: Enveric Biosciences scored higher than 64% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingEnveric Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageEnveric Biosciences has received no research coverage in the past 90 days.Read more about Enveric Biosciences' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Enveric Biosciences are expected to grow in the coming year, from ($2.08) to ($1.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enveric Biosciences is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enveric Biosciences is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnveric Biosciences has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Enveric Biosciences' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.25% of the float of Enveric Biosciences has been sold short.Short Interest Ratio / Days to CoverEnveric Biosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Enveric Biosciences has recently decreased by 2.78%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEnveric Biosciences does not currently pay a dividend.Dividend GrowthEnveric Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.25% of the float of Enveric Biosciences has been sold short.Short Interest Ratio / Days to CoverEnveric Biosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Enveric Biosciences has recently decreased by 2.78%, indicating that investor sentiment is improving. News and Social Media3.2 / 5News SentimentN/A News SentimentEnveric Biosciences has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Enveric Biosciences this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for ENVB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Enveric Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Enveric Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.20% of the stock of Enveric Biosciences is held by insiders.Percentage Held by InstitutionsOnly 13.82% of the stock of Enveric Biosciences is held by institutions.Read more about Enveric Biosciences' insider trading history. Receive ENVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enveric Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ENVB Stock News HeadlinesEnveric Biosciences (NASDAQ:ENVB) Shares Down 8.7% - What's Next?October 18, 2024 | americanbankingnews.comEnveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | finance.yahoo.comWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonOctober 24, 2024 | Porter & Company (Ad)Enveric Biosciences, Inc. (ENVB)August 26, 2024 | nz.finance.yahoo.comEnveric secures patent for radiation dermatitis topical productAugust 15, 2024 | uk.investing.comEnveric Biosciences Reports Second Quarter 2024 Financial and Corporate ResultsAugust 13, 2024 | finance.yahoo.comNon-Hallucinogenic Psychedelic Treatment For Mental Health Disorders Shows Potential To Be Dosed OrallyJuly 25, 2024 | msn.comEnveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed OrallyJuly 25, 2024 | finance.yahoo.comSee More Headlines ENVB Stock Analysis - Frequently Asked Questions How have ENVB shares performed this year? Enveric Biosciences' stock was trading at $1.30 at the beginning of 2024. Since then, ENVB stock has decreased by 57.7% and is now trading at $0.5501. View the best growth stocks for 2024 here. How were Enveric Biosciences' earnings last quarter? Enveric Biosciences, Inc. (NASDAQ:ENVB) issued its quarterly earnings data on Monday, August, 12th. The company reported ($0.25) earnings per share for the quarter, beating analysts' consensus estimates of ($0.55) by $0.30. When did Enveric Biosciences' stock split? Enveric Biosciences shares reverse split on Friday, July 15th 2022. The 1-50 reverse split was announced on Friday, July 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Enveric Biosciences? Shares of ENVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Enveric Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enveric Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), CrowdStrike (CRWD), Palantir Technologies (PLTR), Broadcom (AVGO), ServiceNow (NOW) and Adobe (ADBE). Company Calendar Last Earnings8/12/2024Today10/23/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ENVB CUSIPN/A CIK890821 Webjaypharma.co Phone(239) 302-1707Fax732-243-9254Employees7Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+1,717.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($6.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,290,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-260.30% Return on Assets-164.11% Debt Debt-to-Equity RatioN/A Current Ratio8.56 Quick Ratio8.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book0.77Miscellaneous Outstanding Shares7,954,000Free Float8,813,000Market Cap$4.38 million OptionableNot Optionable Beta0.73 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report This page (NASDAQ:ENVB) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enveric Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enveric Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.